Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional Study.

Community mental health journal·2026

Same author

Assessment of breast cancer and feasibility of subtyping of breast cancer using thoracoabdominal staging photon-counting detector computed tomography.

Scientific reports·2026

Same author

Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis.

Transplantation and cellular therapy·2026

Same author

Divergent Resilience of Bacterial and Fungal Gut Microbiota After Colorectal Surgery: Insights From a Prospective Longitudinal Cohort Study.

MedComm·2026

Same author

mmContext: an open framework for multimodal contrastive learning of omics and text data.

Bioinformatics (Oxford, England)·2026

Same author

Prognostic Impact of UBA1 Expression in Breast Cancer.

Journal of Cancer·2026

Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026

Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026

Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026

Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026

Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026

Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer.

Jasmin Asberger^1,2, Kai Berner^1,2, Anna Bicker^1,2,3

¹Department of Obstetrics and Gynecology, Medical Center-University Hospital Freiburg, 79106 Freiburg, Germany.

|October 28, 2023

Summary

This summary is machine-generated.

MicroRNAs can predict breast cancer treatment response. Extracellular microRNAs miR-100, miR-10b, and miR-182 show promise as circulating biomarkers for therapy response under cyclin-dependent kinase (CDK) inhibition.

Keywords:

CDK inhibitor breast cancer circulating microRNAs disease biomarker microRNAs palbociclib therapy response urinary microRNAs

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

Related Experiment Videos

Last Updated: Jul 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

Area of Science:

Oncology
Molecular Biology
Biomarker Discovery

Background:

Breast cancer is a leading global cancer, with cyclin-dependent kinase (CDK) inhibitors forming a cornerstone of metastatic treatment.
Therapy failures are common, necessitating novel strategies for predicting treatment response.
MicroRNAs (miRNAs) are being investigated as potential biomarkers for therapeutic efficacy.

Purpose of the Study:

To evaluate the biomarker potential of specific microRNAs (miRNAs) for predicting treatment response in breast cancer.
To analyze miRNA expression alterations under palbociclib and letrozole therapy.

Main Methods:

Analysis of intracellular and extracellular miRNA expression levels of 56 miRNAs.
Utilized quantitative polymerase chain reaction (qPCR) on breast cancer cell lines (BT-474, MCF-7, HS-578T).
Investigated miRNA changes under palbociclib monotherapy and combination therapy with letrozole.

Main Results:

A distinct palbociclib-induced miRNA signature was identified both intracellularly and extracellularly.
Intracellular miRNAs (miR-10a, miR-15b, miR-21, miR-23a, miR-23c) showed consistent regulation across cell lines.
Extracellular miRNAs (miR-100, miR-10b, miR-182) were consistently regulated, with miR-17 showing specific regulation in hormone-receptor-positive cells.

Conclusions:

Extracellular miRNAs miR-100, miR-10b, and miR-182 are promising circulating biomarkers for predicting therapy response to CDK inhibitors due to their secretion and upregulation.
Intracellular miRNAs miR-10a, miR-15b, miR-21, miR-23a, and miR-23c represent potential tissue-based biomarkers for treatment response assessment.